New Frontiers on Hyperlipidemia in Pharmaceutical Education

L.K. Kanthal; P Mondal; D Saha; D Mridha; S Mandal.

Research Journal of Pharmacology and Pharmacodynamics

ISSN

2321-5836 (Online)
0975-4407 (Print)

Submit Article

New Frontiers on Hyperlipidemia in Pharmaceutical Education

Author(s): L.K. Kanthal, P Mondal, D Saha, D Mridha, S Mandal.

Email(s): lkkhaldia@gmail.com

DOI: Not Available

Address: L.K. Kanthal*, P. Mondal, D. Saha, D. Mridha and S. Mandal
Bharat Technology, Banitabla, Uluberia, Howrah, W.B. India.
*Corresponding Author

Published In: Volume - 2, Issue - 4, Year - 2010

View HTML

View PDF

ABSTRACT:
The condition of hyperlipidemia can be described as high cholesterol in the blood (hypercholesterolemia), high triglycerides in the blood (hypertriglyceridemia) or it could be both. Hyperlipidemia is a major risk factor in the initiation and progression of atherosclerotic lesions, conditions such as coronary heart disease, ischemic cerebrovascular disease and peripheral vascular disease which leads high morbidity rate in developed countries. The present article gives different classes of anti-hyperlipidemics highlighting the pathophysiology of artherosclerosis, classification, side effects and therapeutic uses of antihyperlipidemics.

Keywords:

Cite this article:
L.K. Kanthal, P Mondal, D Saha, D Mridha, S Mandal. New Frontiers on Hyperlipidemia in Pharmaceutical Education. Research J. Pharmacology and Pharmacodynamics. 2010; 2(4): 257-260.

Cite(Electronic):
L.K. Kanthal, P Mondal, D Saha, D Mridha, S Mandal. New Frontiers on Hyperlipidemia in Pharmaceutical Education. Research J. Pharmacology and Pharmacodynamics. 2010; 2(4): 257-260. Available on: https://rjppd.org/AbstractView.aspx?PID=2010-2-4-13